Zurcher Kantonalbank Zurich Cantonalbank Has $261,000 Stake in DexCom, Inc. (DXCM)

Zurcher Kantonalbank Zurich Cantonalbank lessened its position in DexCom, Inc. (NASDAQ:DXCM) by 75.2% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 4,546 shares of the medical device company’s stock after selling 13,769 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank’s holdings in DexCom were worth $261,000 as of its most recent SEC filing.

Several other large investors have also recently bought and sold shares of DXCM. JPMorgan Chase & Co. raised its position in shares of DexCom by 143.8% in the third quarter. JPMorgan Chase & Co. now owns 2,358,507 shares of the medical device company’s stock valued at $107,170,000 after buying an additional 7,738,678 shares during the last quarter. Janus Henderson Group PLC raised its position in shares of DexCom by 29.2% in the third quarter. Janus Henderson Group PLC now owns 8,819,825 shares of the medical device company’s stock valued at $431,510,000 after buying an additional 1,991,094 shares during the last quarter. Brown Advisory Inc. raised its position in shares of DexCom by 57.2% in the third quarter. Brown Advisory Inc. now owns 4,165,522 shares of the medical device company’s stock valued at $203,798,000 after buying an additional 1,515,134 shares during the last quarter. Frontier Capital Management Co. LLC raised its position in shares of DexCom by 85.0% in the third quarter. Frontier Capital Management Co. LLC now owns 848,670 shares of the medical device company’s stock valued at $41,521,000 after buying an additional 389,947 shares during the last quarter. Finally, Russell Investments Group Ltd. raised its position in shares of DexCom by 1,190.5% in the third quarter. Russell Investments Group Ltd. now owns 333,978 shares of the medical device company’s stock valued at $16,338,000 after buying an additional 308,098 shares during the last quarter.

Shares of DexCom, Inc. (DXCM) opened at $57.34 on Tuesday. The company has a quick ratio of 5.50, a current ratio of 5.86 and a debt-to-equity ratio of 0.84. DexCom, Inc. has a 52 week low of $42.62 and a 52 week high of $86.32.

In other DexCom news, EVP Richard Doubleday sold 1,635 shares of the business’s stock in a transaction that occurred on Friday, November 24th. The shares were sold at an average price of $55.53, for a total transaction of $90,791.55. Following the completion of the sale, the executive vice president now directly owns 65,049 shares in the company, valued at $3,612,170.97. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, insider Terrance H. Gregg sold 10,000 shares of the business’s stock in a transaction that occurred on Tuesday, January 16th. The stock was sold at an average price of $56.86, for a total transaction of $568,600.00. Following the sale, the insider now owns 484,559 shares of the company’s stock, valued at $27,552,024.74. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 33,140 shares of company stock valued at $1,919,541. 1.70% of the stock is owned by insiders.

DXCM has been the subject of a number of analyst reports. Zacks Investment Research lowered shares of DexCom from a “hold” rating to a “sell” rating in a research report on Tuesday, October 24th. TheStreet lowered shares of DexCom from a “c-” rating to a “d+” rating in a research report on Wednesday, October 25th. Northland Securities restated a “hold” rating and issued a $50.00 target price on shares of DexCom in a report on Thursday, November 2nd. Barclays lowered their target price on shares of DexCom from $60.00 to $57.00 and set an “equal weight” rating for the company in a report on Thursday, November 2nd. Finally, Morgan Stanley lowered their target price on shares of DexCom from $72.00 to $52.00 and set a “neutral” rating for the company in a report on Friday, November 3rd. Three analysts have rated the stock with a sell rating, six have given a hold rating and fourteen have assigned a buy rating to the stock. DexCom has a consensus rating of “Hold” and a consensus price target of $67.44.

TRADEMARK VIOLATION NOTICE: This article was reported by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are viewing this article on another website, it was copied illegally and reposted in violation of US & international copyright & trademark law. The correct version of this article can be viewed at https://www.dispatchtribunal.com/2018/02/20/zurcher-kantonalbank-zurich-cantonalbank-has-261000-stake-in-dexcom-inc-dxcm.html.

DexCom Profile

Dexcom, Inc (Dexcom) is a medical device company. The Company is focused on the design, development and commercialization of continuous glucose monitoring (CGM) systems for ambulatory use by people with diabetes and for use by healthcare providers. The Company’s products consist of DexCom G4 PLATINUM and DexCom G5 Mobile.

Institutional Ownership by Quarter for DexCom (NASDAQ:DXCM)

Receive News & Ratings for DexCom Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DexCom and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply